论文部分内容阅读
目的观察盐酸氨溴索联合利巴韦林氧气驱动雾化吸入治疗毛细支气管炎患儿的临床疗效及不良反应。方法将85例毛细支气管炎患儿随机分为对照组30例与观察组55例,两组均予以常规综合治疗,观察组再给予盐酸氨溴索和利巴韦林氧气驱动雾化治疗,观察临床疗效及不良反应。结果观察组的总有效率(96.36%)显著高于对照组(83.33%)(P<0.01),观察组住院时间[(5.3±0.9)d]显著低于对照组[(7.7±1.3)d](P<0.01),氧气驱动雾化吸入过程中未见明显的不良反应发生。但治疗后观察组血氧饱和度与对照组比较差异无统计学意义(P>0.05)。结论氧气驱动雾化吸入盐酸氨溴索和利巴韦林治疗毛细支气管炎患儿的临床疗效显著,是有效、安全的治疗方法。
Objective To observe the clinical efficacy and adverse reactions of ambroxol hydrochloride and ribavirin combined with aerosol-driven atomization inhalation in children with bronchiolitis. Methods Eighty-five children with bronchiolitis were randomly divided into control group (n = 30) and observation group (n = 55). Both groups were treated by conventional combination therapy. Ambroxol hydrochloride and ribavirin Clinical efficacy and adverse reactions. Results The total effective rate (96.36%) in the observation group was significantly higher than that in the control group (83.33%) (P <0.01). The hospitalization time in the observation group was significantly lower than that in the control group [(5.3 ± 0.9) d ] (P <0.01). No obvious adverse reactions occurred during oxygen inhalation aerosol inhalation. However, there was no significant difference in oxygen saturation between the observation group and the control group after treatment (P> 0.05). Conclusion Oxygen-driven aerosol inhalation of ambroxol hydrochloride and ribavirin treatment of bronchiolitis in children with significant clinical efficacy, is an effective and safe treatment.